Compare Stocks: ENTX, XNCR, SEPN, and VIR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTX Entera Bio	$2.86 -1.0%	$2.98	$0.91 ▼ $4.20	$502.64M	1.4	449,380 shs	100,699 shs
SEPN Septerna	$37.71 -0.9%	$39.15	$17.55 ▼ $51.10	$1.76B	2.29	339,168 shs	395,446 shs
VIR Vir Biotechnology	$11.17 -1.1%	$10.19	$4.82 ▼ $11.94	$1.89B	1.59	1.96 million shs	2.18 million shs
XNCR Xencor	$24.84 +0.3%	$24.32	$10.38 ▼ $30.61	$1.84B	0.89	1.37 million shs	1.10 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTX Entera Bio	-1.04%	+4.38%	-2.05%	+72.29%	+52.94%
SEPN Septerna	-0.89%	-0.16%	+0.56%	+10.91%	+98.47%
VIR Vir Biotechnology	-1.06%	+4.78%	-2.87%	+11.25%	+95.96%
XNCR Xencor	+0.28%	+4.37%	-7.66%	+65.60%	+109.97%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTX Entera Bio	$2.86 -1.0%	$2.98	$0.91 ▼ $4.20	$502.64M	1.4	449,380 shs	100,699 shs
SEPN Septerna	$37.71 -0.9%	$39.15	$17.55 ▼ $51.10	$1.76B	2.29	339,168 shs	395,446 shs
VIR Vir Biotechnology	$11.17 -1.1%	$10.19	$4.82 ▼ $11.94	$1.89B	1.59	1.96 million shs	2.18 million shs
XNCR Xencor	$24.84 +0.3%	$24.32	$10.38 ▼ $30.61	$1.84B	0.89	1.37 million shs	1.10 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTX Entera Bio	-1.04%	+4.38%	-2.05%	+72.29%	+52.94%
SEPN Septerna	-0.89%	-0.16%	+0.56%	+10.91%	+98.47%
VIR Vir Biotechnology	-1.06%	+4.78%	-2.87%	+11.25%	+95.96%
XNCR Xencor	+0.28%	+4.37%	-7.66%	+65.60%	+109.97%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENTX Entera Bio	2.83	Moderate Buy	$9.60	235.66% Upside
SEPN Septerna	2.82	Moderate Buy	$52.44	39.07% Upside
VIR Vir Biotechnology	2.88	Moderate Buy	$21.57	93.12% Upside
XNCR Xencor	2.64	Moderate Buy	$34.00	36.88% Upside

Current Analyst Ratings Breakdown

Latest ENTX, XNCR, SEPN, and VIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	XNCR Xencor	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$55.00
9/28/2026	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy
9/28/2026	XNCR Xencor	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$27.00 ➝ $29.00
9/24/2026	ENTX Entera Bio	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
9/24/2026	ENTX Entera Bio	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/23/2026	ENTX Entera Bio	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
9/22/2026	ENTX Entera Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
9/21/2026	XNCR Xencor	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/21/2026	XNCR Xencor	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$20.00 ➝ $26.00
9/18/2026	ENTX Entera Bio	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$9.00
9/18/2026	ENTX Entera Bio	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$9.00

(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENTX Entera Bio	N/A	N/A	N/A	N/A	$0.29 per share	N/A
SEPN Septerna	$98.88M	17.80	N/A	N/A	$8.53 per share	4.42
VIR Vir Biotechnology	$302.59M	6.25	N/A	N/A	$5.50 per share	2.03
XNCR Xencor	$104.97M	17.59	N/A	N/A	$8.90 per share	2.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENTX Entera Bio	-$11.44M	-$0.35	N/A	N/A	N/A	N/A	-147.19%	-103.22%	11/13/2026 (Estimated)
SEPN Septerna	-$48.88M	-$0.54	N/A	N/A	N/A	-24.51%	-9.57%	-6.28%	11/9/2026 (Estimated)
VIR Vir Biotechnology	-$437.99M	-$1.86	N/A	N/A	N/A	N/A	-29.99%	-23.62%	11/4/2026 (Estimated)
XNCR Xencor	-$91.92M	-$2.17	N/A	N/A	N/A	-155.59%	-28.66%	-20.38%	11/4/2026 (Estimated)

Latest ENTX, XNCR, SEPN, and VIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	SEPN Septerna	-$0.4260	-$0.29	+$0.1360	-$0.29	$19.22 million	$26.75 million
8/7/2026	Q2 2026	ENTX Entera Bio	-$0.08	-$0.14	-$0.06	-$0.14	N/A	N/A
8/5/2026	Q2 2026	VIR Vir Biotechnology	$0.3326	$0.47	+$0.1374	$0.47	$135.88 million	$238.95 million
8/5/2026	Q2 2026	XNCR Xencor	-$0.8015	-$0.29	+$0.5115	-$0.29	$18.89 million	$51.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
SEPN Septerna	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENTX Entera Bio	N/A	8.98	8.98
SEPN Septerna	N/A	4.99	4.99
VIR Vir Biotechnology	N/A	6.04	6.04
XNCR Xencor	N/A	6.39	6.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENTX Entera Bio	14.11%
SEPN Septerna	N/A
VIR Vir Biotechnology	65.32%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
ENTX Entera Bio	10.57%
SEPN Septerna	5.80%
VIR Vir Biotechnology	2.90%
XNCR Xencor	5.08%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENTX Entera Bio	21	173.92 million	155.54 million	Optionable
SEPN Septerna	130	46.68 million	43.97 million	N/A
VIR Vir Biotechnology	367	169.22 million	164.31 million	Optionable
XNCR Xencor	260	74.35 million	70.58 million	Optionable

ENTX, XNCR, SEPN, and VIR Headlines

Recent News About These Companies

Xencor (NASDAQ:XNCR) Stock Picked Up by Analysts at Wells Fargo & Company

October 2 at 1:42 AM | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and IQVIA Holdings (IQV)

September 30 at 6:43 PM | theglobeandmail.com

Wells Fargo & Company Initiates Coverage on Xencor (NASDAQ:XNCR)

September 30 at 10:05 AM | marketbeat.com

Xencor stock falls 3.52 percent as Truist lifts its target

September 29, 2026 | ad-hoc-news.deA

Xencor (NASDAQ:XNCR) Shares Climb 4.6% - Should You Buy?

September 28, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Earns Buy Rating from Truist Financial

September 28, 2026 | marketbeat.com

Xencor, Inc. $XNCR Shares Newly Bought by Bank of America Corp DE

September 28, 2026 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Stock Has Average Price Target of $31.12 According to Brokerages

September 26, 2026 | americanbankingnews.com

Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages

September 26, 2026 | marketbeat.com

Xencor's XmAb819 Data Could Support Registrational Path, Wedbush Says

September 25, 2026 | finance.yahoo.com

Xencor (NASDAQ:XNCR) Stock Price Expected to Rise, Bank of America Analyst Says

September 23, 2026 | americanbankingnews.com

Xencor (NASDAQ:XNCR) Price Target Raised to $26.00

September 21, 2026 | marketbeat.com

BofA Adjusts Price Target on Xencor to $26 From $20, Keeps Neutral Rating

September 21, 2026 | marketscreener.comM

Xencor stock steadies after recent earnings, analysts watch pipeline progress

September 19, 2026 | ad-hoc-news.deA

Hsbc Holdings PLC Has $2.08 Million Position in Xencor, Inc. $XNCR

September 12, 2026 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 260,752 Shares of Xencor, Inc. $XNCR

September 9, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Buys Shares of 49,696 Xencor, Inc. $XNCR

September 6, 2026 | marketbeat.com

Seven Fleet Capital Management LP Has $5.93 Million Stake in Xencor, Inc. $XNCR

September 5, 2026 | marketbeat.com

Man Group plc Takes Position in Xencor, Inc. $XNCR

September 4, 2026 | marketbeat.com

Bank of New York Mellon Corp Makes New Investment in Xencor, Inc. $XNCR

September 4, 2026 | marketbeat.com

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Xencor (NASDAQ:XNCR) Stock

September 3, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX, XNCR, SEPN, and VIR Company Descriptions

Entera Bio NASDAQ:ENTX

$2.86 -0.03 (-1.04%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.88 +0.02 (+0.70%)

As of 10/2/2026 07:30 PM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Septerna NASDAQ:SEPN

$37.71 -0.34 (-0.89%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$37.66 -0.05 (-0.15%)

As of 10/2/2026 07:30 PM Eastern

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all U.S. Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75% of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the state-of-the-art technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug discovery, particularly the development of novel oral small molecules, such as agonists (which activate GPCR signaling) for peptide GPCRs and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands). Our proprietary Native Complex Platform™ replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our Native Complex PlatformTM is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists (which inhibit GPCR signaling), and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline, is focused initially on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women's health, cardiovascular, and respiratory disease. --- Leveraging our team, scientific and technical advisors, and our proprietary Native Complex Platform™, we aim to be a leader in the development of oral GPCR-targeted medicines for patients with significant unmet needs. We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California.

Vir Biotechnology NASDAQ:VIR

$11.17 -0.12 (-1.06%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$11.00 -0.17 (-1.52%)

As of 10/2/2026 07:38 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Xencor NASDAQ:XNCR

$24.84 +0.07 (+0.28%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$25.05 +0.21 (+0.85%)

As of 10/2/2026 07:41 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENTX, XNCR, SEPN, and VIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENTX, XNCR, SEPN, and VIR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENTX, XNCR, SEPN, and VIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX, XNCR, SEPN, and VIR Company Descriptions

Entera Bio NASDAQ:ENTX

Septerna NASDAQ:SEPN

Vir Biotechnology NASDAQ:VIR

Xencor NASDAQ:XNCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENTX, XNCR, SEPN, and VIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENTX, XNCR, SEPN, and VIR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENTX, XNCR, SEPN, and VIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX, XNCR, SEPN, and VIR Company Descriptions

Entera Bio NASDAQ:ENTX

Septerna NASDAQ:SEPN

Vir Biotechnology NASDAQ:VIR

Xencor NASDAQ:XNCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools